z895r12

Property	Value
?:abstract	OBJECTIVES: To report clinician-perceived changes to cancer service delivery in response to COVID-19. DESIGN: Multidisciplinary Australasian cancer clinician survey in collaboration with the European Society of Medical Oncology. SETTING: Between May and June 2020 clinicians from 70 countries were surveyed; majority from Europe (n=196; 39%) with 1846 COVID-19 cases per million people, Australia (AUS)/New Zealand (NZ) (n=188; 38%) with 267/236 per million and Asia (n=75; 15%) with 121 per million at time of survey distribution. PARTICIPANTS: Medical oncologists (n=372; 74%), radiation oncologists (n=91; 18%) and surgical oncologists (n=38; 8%). RESULTS: Eighty-nine per cent of clinicians reported altering clinical practices; more commonly among those with versus without patients diagnosed with COVID-19 (n=142; 93% vs n=225; 86%, p=0.03) but regardless of community transmission levels (p=0.26). More European clinicians (n=111; 66.1%) had treated patients diagnosed with COVID-19 compared with Asia (n=20; 27.8%) and AUS/NZ (n=8; 4.8%), p<0.001. Many clinicians (n=307; 71.4%) reported concerns that reduced access to standard treatments during the pandemic would negatively impact patient survival. The reported proportion of consultations using telehealth increased by 7.7-fold, with 25.1% (n=108) of clinicians concerned that patient survival would be worse due to this increase. Clinicians reviewed a median of 10 fewer outpatients/week (including non-face to face) compared with prior to the pandemic, translating to 5010 fewer specialist oncology visits per week among the surveyed group. Mental health was negatively impacted for 52.6% (n=190) of clinicians. CONCLUSION: Clinicians reported widespread changes to oncology services, in regions of both high and low COVID-19 case numbers. Clinician concerns of potential negative impacts on patient outcomes warrant objective assessment, with system and policy implications for healthcare delivery at large.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/7z895r12_hasAnnotation_C0006826> <https://research.tib.eu/covid-19/entity/7z895r12_hasAnnotation_C0027651> <https://research.tib.eu/covid-19/entity/7z895r12_hasAnnotation_C1825598> <https://research.tib.eu/covid-19/entity/7z895r12_hasAnnotation_C5392207>
?:creator	<https://research.tib.eu/covid-19/entity/Chazan%2C_Grace%3B_Franchini%2C_Fanny%3B_Alexander%2C_Marliese%3B_Banerjee%2C_Susana%3B_Mileshkin%2C_Linda%3B_Blinman%2C_Prunella%3B_Zielinski%2C_Rob%3B_Karikios%2C_Deme%3B_Pavlakis%2C_Nick%3B_Peters%2C_Solange%3B_Lordick%2C_Florian%3B_Ball%2C_David%3B_Wright%2C_Gavin%3B_IJzerman%2C_Maarten%3B_Solomon%2C_Benjamin>
?:doi	10.1136/esmoopen-2020-001090
?:doi	<https://research.tib.eu/covid-19/entity/10.1136/esmoopen-2020-001090>
?:journal	ESMO_Open
?:license	cc-by-nc
?:pdf_json_files	document_parses/pdf_json/86464d5e5c24ca6db34664a3f1908944ff296a6f.json
?:pmc_json_files	document_parses/pmc_json/PMC7709494.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7709494>
?:pmid	<https://research.tib.eu/covid-19/entity/33262203.0>
?:pmid	33262203.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/86464d5e5c24ca6db34664a3f1908944ff296a6f>
?:source	Medline; PMC
?:title	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-12-01

Property

Value

?:abstract

OBJECTIVES: To report clinician-perceived changes to cancer service delivery in response to COVID-19. DESIGN: Multidisciplinary Australasian cancer clinician survey in collaboration with the European Society of Medical Oncology. SETTING: Between May and June 2020 clinicians from 70 countries were surveyed; majority from Europe (n=196; 39%) with 1846 COVID-19 cases per million people, Australia (AUS)/New Zealand (NZ) (n=188; 38%) with 267/236 per million and Asia (n=75; 15%) with 121 per million at time of survey distribution. PARTICIPANTS: Medical oncologists (n=372; 74%), radiation oncologists (n=91; 18%) and surgical oncologists (n=38; 8%). RESULTS: Eighty-nine per cent of clinicians reported altering clinical practices; more commonly among those with versus without patients diagnosed with COVID-19 (n=142; 93% vs n=225; 86%, p=0.03) but regardless of community transmission levels (p=0.26). More European clinicians (n=111; 66.1%) had treated patients diagnosed with COVID-19 compared with Asia (n=20; 27.8%) and AUS/NZ (n=8; 4.8%), p<0.001. Many clinicians (n=307; 71.4%) reported concerns that reduced access to standard treatments during the pandemic would negatively impact patient survival. The reported proportion of consultations using telehealth increased by 7.7-fold, with 25.1% (n=108) of clinicians concerned that patient survival would be worse due to this increase. Clinicians reviewed a median of 10 fewer outpatients/week (including non-face to face) compared with prior to the pandemic, translating to 5010 fewer specialist oncology visits per week among the surveyed group. Mental health was negatively impacted for 52.6% (n=190) of clinicians. CONCLUSION: Clinicians reported widespread changes to oncology services, in regions of both high and low COVID-19 case numbers. Clinician concerns of potential negative impacts on patient outcomes warrant objective assessment, with system and policy implications for healthcare delivery at large.

is ?:annotates of